ANAB today
$48.77+$0.39 (+0.81%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourBullish
15 minBullish
5 minConsolidating
Daily trend turns up above $51.85
Key levels
Resistance$51.85
Resistance$49.71
Support$47.19
Support$44.02
Latest news & SEC filings
ProductGSK reports positive Phase II AZUR-1 results for Jemperli
ProductUS regulator clears dostarlimab for late-stage rectal cancer
AnalystJP Morgan keeps Overweight rating on AnaptysBio, cuts price target to $60
All ANAB news →About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company that creates antibody-based medicines for immune and inflammatory conditions. Its own candidates include rosnilimab for rheumatoid arthritis, ANB033 for celiac disease and eosinophilic esophagitis, and ANB101 for autoimmune disorders. It also out-licenses antibody programs to partners such as GSK and Vanda Pharmaceuticals, earning milestone and royalty payments.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
ANAPTYSBIO, INC (ANAB)
What Is the Price Target for ANAB?
SEPT Low Target
$60.00
SEPT Mid Target
$76.00
SEPT High Target
$95.00
Analyst Consensus
$76.00
Is ANAB a Buy or Sell Right Now?
Thesis
- •Revenue growing 157.0% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ANAB.
Start Free Trial →Is ANAB Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$65.82
15
Moat Score
NONE
4/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with ANAB?
Insider Signal
SELLING
0 buys / 17 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| RENTON HOLLINGS | director | Buy | 5,000 | $90K | Oct 1, 2026 |
| RENTON HOLLINGS | director | Sale | 5,000 | $249K | Oct 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ANAB Growth Story
Revenue YoY
157.0%
3yr Revenue CAGR
183.6%
EPS Growth YoY
91.02%
FCF Growth YoY
114.5%
Revenue Trend
ACCELERATING
Dark Pool Trades for ANAB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ANAB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:24 | $48.77 | 1,478 | $$72K | BUY |
| 19:37:22 | $48.73 | 1,000 | $$49K | MIDPOINT |
| 14:30:05 | $48.99 | 5,000 | $$245K | BUY |
| 21:00:54 | $48.38 | 2,930 | $$142K | BUY |
| 20:59:25 | $48.39 | 1,000 | $$48K | BUY |
5 dark pool trades shown · $$556K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ANAB
PREVIEWSEPT Investing provides real-time options flow tracking for ANAB, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $45 | Nov 20 | 9 | $$1680 | 3 | SWEEP |
| CALL | $45 | Nov 20 | 9 | $$560 | 1 | SWEEP |
| CALL | $65 | Nov 20 | 9 | $$385 | 11 | SWEEP |
3 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ANAPTYSBIO, INC (ANAB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ANAB — frequently asked questions
What is ANAB stock price today?
ANAPTYSBIO, INC (ANAB) is at $48.77, up 0.81% (+$0.39) at the Nov 11, 2026 close.
Why is ANAB stock moving today?
Latest ANAB news — Oct 26, 2026: GSK reports positive Phase II AZUR-1 results for Jemperli · Oct 19, 2026: US regulator clears dostarlimab for late-stage rectal cancer
What is the ANAB price target?
The average analyst price target for ANAB is $76.00, ranging from $60 to $95, based on 7 analysts. Latest: JP Morgan maintains on Sep 30, 2026.
What do analysts rate ANAB?
Analyst ratings for ANAB: 0 Buy, 13 Hold, 0 Sell — consensus Hold.
Did ANAB beat earnings?
ANAB last reported on Sep 21, 2026: EPS $5.11 vs $5.11 expected — in line.
Does ANAB pay a dividend?
ANAB does not currently pay a dividend.
What are ANAB support and resistance levels?
Support: $47.19, $44.02, $39.02. Resistance: $49.71, $51.85, $56.04.
What are insiders doing with ANAB?
Insider activity: SELLING, 0 buys and 17 sells in the last 90 days.
What is the latest news on ANAB?
Oct 26, 2026: GSK reports positive Phase II AZUR-1 results for Jemperli · Oct 19, 2026: US regulator clears dostarlimab for late-stage rectal cancer · Sep 30, 2026: JP Morgan keeps Overweight rating on AnaptysBio, cuts price target to $60